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Antimicrobial resistance represents a major threat 
to global health and security. In 2014, the World 
Health Assembly called on all nations and the 
international community to take every necessary 
measure to control it, including surveillance of 
its emergence and spread.1
The development of drug resistance in Myco-
bacterium tuberculosis was first documented in the 
late 1940s, soon after antibiotic therapy was in-
troduced for tuberculosis treatment.2 It quickly 
became obvious that combination chemotherapy 
could prevent the emergence of drug resistance3 
and that patients infected with drug-resistant 
strains were less likely to be cured.4 Neverthe-
less, it was only in the early 1990s that drug-
resistant tuberculosis began to receive global 
attention as a public health threat. This coincided 
with the detection of outbreaks of multidrug-
resistant (MDR) tuberculosis (defined as resis-
tance to at least rifampin and isoniazid) that 
were associated with high mortality among pa-
tients coinfected with the human immunodefi-
ciency virus (HIV).5-8 The urgent need for a global 
mechanism to monitor the emergence and spread 
of resistance to antituberculosis drugs became 
clear.
In 1994, the Global Tuberculosis Program of 
the World Health Organization (WHO), with the 
support of the International Union against Tuber-
culosis and Lung Disease (the Union), estab-
lished the Global Project on Anti-Tuberculosis 
Drug Resistance Surveillance (hereafter referred 
to as “the project”) to measure the magnitude of 
drug resistance and to monitor trends. This 
project remains the oldest and largest initiative 
on the surveillance of antimicrobial resistance in 
the world.9 In this article, we describe the history 
of global surveillance of drug resistance in tuber-
culosis and discuss methods for surveillance, 
the quality of available data, the key achievements 
and findings to date, the main challenges that 
remain, and future directions.
History of Global Surveill ance 
of Resistance to Antituberculosis 
Drugs
Throughout its existence, the project has been 
hosted by the WHO and supported by the TB 
Supranational Reference Laboratory (SRL) Net-
work and several technical agencies. Funding has 
been continuously provided by the U.S. Agency 
for International Development.
The foundations of the project were laid in 
1993 and 1994. A first meeting of interested 
partners was organized at the annual interna-
tional conference of the Union in October 1993. 
Investigators from the Dominican Republic, 
Kenya, and Zimbabwe committed to implement 
the first drug-resistance surveys using a standard-
ized approach. In June 1994, at a meeting orga-
nized by the WHO and the Union in Mainz, 
Germany, a group of 14 laboratories established 
the SRL Network to conduct and ensure quality-
assured testing of drug susceptibility, under the 
leadership of the Laboratory Centre for Disease 
Control in Ottawa. Meanwhile, the WHO issued 
guidelines on standardized methods for conduct-
ing surveys of antituberculosis-drug resistance, 
which have been regularly updated.10-14 Surveil-
lance data are collected either through continu-
ous surveillance systems based on routine test-
ing of all patients with tuberculosis or periodic 
surveys, which are discrete studies measuring 
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drug resistance among a selected sample of pa-
tients who are representative of an entire popu-
lation of patients with tuberculosis. These stan-
dardized methods allow comparability of data 
within countries over time as well as between 
countries.
Since 1999, the SRL Network has been coor-
dinated by the Institute of Tropical Medicine in 
Antwerp, Belgium, and it currently comprises 
33 laboratories distributed across all continents. 
Proficiency testing is conducted annually, and 
results are published regularly.15-17 Starting in 
2006, soon after the recognition of extensively 
drug-resistant (XDR) tuberculosis (defined as 
MDR tuberculosis plus resistance to a fluoroquin-
olone and at least one second-line injectable 
agent: amikacin, kanamycin, or capreomycin) as 
an emerging threat worldwide,18,19 the panel of 
drugs tested as part of the project was expanded 
to include fluoroquinolones and second-line in-
jectable agents for all patients who had received 
a diagnosis of MDR tuberculosis.
The first global report on antituberculosis-
drug resistance was published by the WHO in 
1997 with results from surveys conducted in 35 
countries. By 2010, a total of five global reports 
had been published.20-24 Subsequently, drug-resis-
tance surveillance data have been published an-
nually in the WHO Global Tuberculosis Report, 
allowing rapid sharing of data soon after they 
become available by incorporating them along-
side other aspects of tuberculosis surveillance. To 
ensure wide dissemination and allow in-depth 
analysis of specific topics, including trends, data 
have also been regularly published in peer-reviewed 
journals.25-32
Key Achievements
Wide Geographic Coverage of Data  
on Antituberculosis-Drug Resistance
By 2014, representative data on antituberculosis-
drug resistance that were derived from continu-
ous surveillance or periodic surveys conducted 
with the use of standardized methods had been 
made available from 153 countries, covering 96% 
of the world’s population and incident tubercu-
losis cases (Fig. 1). Only 41 countries, account-
ing for 4% of the world’s population and inci-
dent tuberculosis cases, have never conducted a 
survey and therefore still rely on weaker model-
based estimates of the prevalence of drug resis-
tance. A total of 80 of the 153 countries have 
continuous surveillance systems, and the remain-
ing 73 have relied on periodic surveys. The latter 
group includes most resource-limited settings, 
in which the burden of tuberculosis and MDR 
tuberculosis is the highest but a shortage of 
laboratory capacity and inadequate financial and 
human resources have precluded testing every 
patient with tuberculosis for drug resistance.33
Measurement of Levels of MDR Tuberculosis 
in 153 Countries
The most recent data on the percentage of pa-
tients with newly diagnosed tuberculosis who 
have MDR tuberculosis are shown in Figure 2. 
The percentage remains stable, at 3% or lower, 
Figure 1. Global Coverage of Surveillance Data on Resistance to First-Line Antituberculosis Drugs, 1995–2015.
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in most parts of the world. However, countries in 
Eastern Europe and central Asia have serious 
MDR tuberculosis epidemics. This suggests that 
the severe disruptions of drug supply after the 
collapse of the Soviet Union may have led to 
mismanagement of patient care, generating high 
levels of MDR tuberculosis. The highest measured 
levels of MDR tuberculosis among patients with 
newly diagnosed tuberculosis are in Belarus 
(34.1% in 2014), Estonia (19.5% in 2014), Kazakh-
stan (25.2% in 2013), Kyrgyzstan (26.4% in 2011), 
Moldova (23.7% in 2012), Russia (average across 
regions with data, 19.3% in 2012), Ukraine (24.0% 
in 2014), and Uzbekistan (23.2% in 2011).33
Among patients with previously diagnosed 
tuberculosis, the percentages with MDR tuber-
culosis were the highest in Belarus (69.1% in 
2014), Estonia (62.1% in 2014), Kazakhstan (57.8% 
in 2013), Kyrgyzstan (55.1% in 2013), Moldova 
(62.3% in 2012), Tajikistan (52.2% in 2014), and 
Uzbekistan (62.0% in 2011). In Russia, even 
though the average percentage of patients with 
previously treated tuberculosis who have MDR 
tuberculosis does not exceed 50%, the percent-
age is well above 50% in several regions.34
A Time-Trend Analysis Based on Data  
from 100 Countries
During the previous two decades, 100 countries 
have repeated a drug-resistance survey at least 
once; of these, 65 have at least 3 years of data. 
For settings with three or more data points, per 
capita rates of MDR tuberculosis between 1999 
and 2014 were calculated by multiplying the 
notification rate of new cases of tuberculosis 
reported annually to the WHO by the percentage 
of patients with MDR tuberculosis among pa-
tients with newly diagnosed tuberculosis reported 
in the same setting and year. The rate of MDR 
tuberculosis is defined as the annual number of 
estimated new cases of MDR tuberculosis per 
100,000 population, and the notification rate of 
new cases of tuberculosis is defined as the an-
nual number of new cases of tuberculosis occur-
ring in notified patients per 100,000 population. 
The statistical significance of trends were as-
sessed by testing the null hypothesis of no linear 
trend. More details on the methods are de-
scribed elsewhere.32,35 The average annual per-
centage change in the rates of tuberculosis and 
MDR tuberculosis were calculated for all coun-
tries and subnational settings with significant 
linear trends (Fig. 3).
Significant trends in per capita rates of MDR 
tuberculosis among notified patients with newly 
diagnosed tuberculosis were detected in 12 coun-
tries. Decreasing trends were found in Australia, 
Estonia, Hong Kong, Israel, Latvia, Portugal, and 
the United States, ranging from a change of −5% 
to −9% per annum. Increasing trends were de-
tected in the Tomsk Oblast region of Russia 
(13% per annum) and also in Austria, Finland, 
Sweden, and the United Kingdom. In this group 
of western European countries, increasing trends 
are associated with immigration.36 Limited data 
on trends are available from African and Asian 
Figure 2. Percentage of Patients with Newly Diagnosed Tuberculosis Who Have Multidrug-Resistant (MDR) Tuberculosis.
The figure reflects the most recent year for which data have been reported, which varies among countries.
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countries owing to the challenges in repeating 
surveys at regular intervals or establishing con-
tinuous surveillance. As a consequence, our under-
standing of the evolution of the MDR tuberculo-
sis epidemic in these regions is very limited.
Evidence of an Association between MDR 
Tuberculosis and Other Factors
The association between MDR tuberculosis and 
HIV infection at the population level varies from 
setting to setting. A positive association has 
been found in Eastern European countries,31,37 
and a recent systematic review showed a moder-
ate association with HIV infection, particularly 
in patients with newly diagnosed tuberculosis.38 
However, on a global level, currently available 
data do not show a clear, consistent relationship 
between the levels of HIV infection and MDR 
tuberculosis in a population.
An analysis of the levels of MDR tuberculosis 
in different age groups suggested that children 
with tuberculosis did not have a lower risk of 
MDR tuberculosis than adult patients, with simi-
lar percentages of patients with MDR tuberculo-
sis in both groups.30 This finding should, how-
ever, be interpreted with caution, because any 
analysis of surveillance data on childhood tuber-
culosis is limited by the challenges associated 
with the bacteriologic diagnosis of tuberculosis 
and the detection of drug resistance in children.
Reliable Estimates of the Global Burden  
of MDR Tuberculosis (Cases and Deaths)
On average worldwide, 3.3% of patients with 
newly diagnosed tuberculosis (95% confidence 
interval [CI], 2.2 to 4.4) and 20.1% of those with 
previously treated tuberculosis (95% CI, 13.8 to 
27.5) are estimated to have MDR tuberculosis.33 
Data on levels of drug resistance in patients with 
newly diagnosed and previously treated tubercu-
losis can be combined with other data on tuber-
culosis incidence and mortality to produce global 
estimates of the disease burden associated with 
MDR tuberculosis. The latest estimates suggest 
that there were 480,000 incident cases of MDR 
tuberculosis (range, 360,000 to 600,000) and 
190,000 deaths from the disease (range, 120,000 
to 260,000) in 2013. The methods used to pro-
duce these estimates are described in detail 
elsewhere.33
XDR Tuberculosis Reported from 105 Countries
By December 2014, cases of XDR tuberculosis 
had been reported by 105 countries. A total of 
83 countries reported representative data from 
continuous surveillance or periodic surveys on 
the percentage of patients with MDR tuberculo-
sis who had XDR tuberculosis. When these data 
were combined, the average percentage was 
9.7% (95% CI, 7.4 to 12.1). Fourteen of these 
countries reported 10 or more cases of XDR tu-
berculosis in the most recent year for which data 
were available. Among these countries, the per-
centage of patients with MDR tuberculosis who 
had XDR tuberculosis was highest in Belarus 
(29.3% in 2014), Georgia (15.1% in 2014), Latvia 
(18.6% in 2014), and Lithuania (24.7% in 2013).33
Increase in Patients with MDR Tuberculosis 
Who Were Receiving Second-Line Therapy
Globally in 2014, a total of 123,000 patients with 
MDR or rifampin-resistant tuberculosis were 
notified. This was equivalent to 41% of the pa-
tients estimated to have MDR tuberculosis among 
those who were reported to have pulmonary tu-
berculosis in the same year (see the Global 
Tuberculosis Report 201533 for the details of this 
estimate). This is a reflection of the still very 
limited access to drug-susceptibility testing in 
most countries: globally in 2014, only 12% of 
patients with newly diagnosed tuberculosis and 
58% of those with previously treated tuberculo-
sis underwent testing for drug resistance. Patients 
with MDR tuberculosis or rifampin-resistant tu-
berculosis would be treated with second-line 
drugs. A total of 111,000 patients with tubercu-
losis began second-line therapy in 2014, an in-
crease of 14% as compared with 2013. Globally, 
the ratio of patients receiving second-line ther-
apy to notified patients with MDR tuberculosis 
was 90%. Although the rate of treatment success 
remained stagnant at around 50% between 2007 
Figure 3 (facing page). Time Trends in MDR Tuberculosis.
Shown are rates per 100,000 population of new cases 
of tuberculosis (black circles) and cases of MDR tuber‑
culosis among patients with newly diagnosed tubercu‑
losis (red circles) in countries or regions with signifi‑
cant linear decreasing trends (Panel A) or increasing 
trends (Panel B) in MDR tuberculosis. The mean change 
per year is given as a percentage. The y axes are on a 
log scale.
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and 2012, more than 100,000 patients worldwide 
were successfully treated in these six annual 
cohorts alone.33
Figure 4 compares the number of patients 
who were successfully treated with second-line 
regimens with the estimated number of patients 
with MDR tuberculosis among patients with 
pulmonary tuberculosis notified in 2012. None 
of these countries have managed to cure all of 
their estimated MDR tuberculosis burden, reflect-
ing persistent barriers to the diagnosis of cases 
and the initiation of appropriate treatment, as 
well as the relative ineffectiveness of second-line 
regimens for MDR tuberculosis.39 Only if more 
countries, especially those with large numbers 
of patients with MDR tuberculosis, take bold 
actions to address these three critical points 
separately will there be any substantial effect on 
the global burden of disease and death due to 
MDR tuberculosis. In addition, more efforts 
are needed to find more cases of tuberculosis: 
9.6 million cases of tuberculosis were estimated 
to have occurred in 2014, but one third of the 
patients were not notified and the burden of re-
sistance among these patients is unknown.
Remaining Challenges
After 20 years of global surveillance of resis-
tance to antituberculosis drugs, three main chal-
lenges remain. These are a lack of trend data for 
many resource-limited countries (particularly in 
Africa and Asia), owing to insufficient capacity 
to conduct repeat surveys at regular intervals or 
to establish continuous surveillance of drug 
resistance; limited understanding of in-country 
geographic distribution of drug resistance and 
limited capacity to detect outbreaks and hot-spot 
areas; and limited engagement of private health 
providers in surveys, resulting in an inability to 
assess the scale of drug resistance outside cases 
detected in the public sector.
Routine testing of all patients with tuberculo-
sis is widely recognized as the most appropriate 
surveillance approach for monitoring trends in 
drug resistance and detecting outbreaks and hot-
spot regions.40 However, in most resource-limited 
countries in which the burden of tuberculosis 
and MDR tuberculosis is the highest, routine 
drug-susceptibility testing is not yet accessible 
to all patients owing to insufficient laboratory 
capacity, infrastructure (including deficiencies in 
transportation of specimens and in data collec-
tion and management), or resources. Although a 
surveillance system for tuberculosis exists in 
most countries, the complexities associated with 
drug-resistance testing do not permit routine 
drug-susceptibility testing on all patients with 
newly diagnosed tuberculosis. The establishment 
of continuous surveillance systems for drug re-
sistance can overcome two of the above-men-
tioned major challenges: a lack of understanding 
of trends in drug resistance and the inability to 
accurately describe the heterogeneity of the epi-
demic within countries and detect hot-spot areas 
and disease outbreaks.
The third major challenge is a general lack of 
data on the magnitude of drug resistance out-
side the public sector. In large parts of the 
world, particularly in Asia, many patients with 
symptoms of tuberculosis seek care from private 
health care providers and may never reach public 
facilities or reach those linked to the national 
tuberculosis-control program only at a later stage, 
if the treatment they received from private pro-
viders was ineffective or too costly.41 Private 
providers are involved in drug-resistance surveys 
Figure 4. Estimated Number of Patients with MDR Tuberculosis and Number 
of Patients Who Were Successfully Treated (2012 Cohort).
Countries with more than 1000 estimated patients with MDR tuberculosis 
and more than 0 patients who were successfully treated with second‑line 
therapy are presented. The diagonal line represents the line of identity. Both 
axes of the graph are on a log scale. DR Congo denotes the Democratic 
Republic of Congo.
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only if they are linked to the national tuberculo-
sis-control program through formal agreements. 
As a result, current drug-resistance surveillance 
data may underestimate or overestimate the true 
magnitude of the problem, especially in coun-
tries with a large private health sector that is 
involved in tuberculosis care.
The Nex t Dec ade
The next 10 years of surveillance of antitubercu-
losis-drug resistance should see considerable 
evolution, including developments that address 
the three main challenges that exist today. Since 
2009, molecular technologies have been increas-
ingly incorporated into drug-resistance surveys. 
In particular, Xpert MTB/RIF (Cepheid) is being 
used in several Asian and African countries to 
detect specimens with rifampin resistance and 
identify those requiring testing for additional 
drugs at a reference laboratory. Rifampin resis-
tance is the most important indicator of MDR 
tuberculosis and has implications for treatment 
regimens. This approach simplifies logistics (e.g., 
sample transportation), greatly reduces labora-
tory workload, and cuts costs.14,42 In the future, 
it is likely that molecular technologies will re-
place conventional phenotypic testing in drug-
resistance surveys and surveillance. This includes 
high-throughput sequencing-based technologies, 
which are already used for research purposes in 
some reference laboratories of resource-limited 
countries. These technologies are expected to be-
come standard tools for surveillance as the costs 
of equipment and tests continue to fall and under-
standing of the clinical significance of muta-
tions in the M. tuberculosis genome improves.43
The use of molecular technologies could re-
solve the persistent difficulties that have con-
strained monitoring of drug-resistance trends 
in most resource-constrained countries and have 
limited the ability to detect disease outbreaks. 
For example, the establishment of continuous 
surveillance systems using Xpert MTB/RIF would 
allow the monitoring of trends in rifampin resis-
tance, an accurate description of variations in the 
levels of resistance within a country, and prompt 
detection of hot-spot regions.14
Rifampin and isoniazid remain the most 
powerful bactericidal first-line antituberculosis 
drugs. However, promising shorter treatment reg-
imens with fluoroquinolones and pyrazinamide 
are currently being evaluated and could become 
the cornerstones of tuberculosis treatment in the 
future.44 Data on the background prevalence of 
resistance to f luoroquinolones (in particular, 
moxifloxacin and gatifloxacin) and pyrazinamide 
are therefore essential for assessing the feasibility 
of introducing new treatment regimens and guid-
ing laboratory practices and diagnostic algo-
rithms. Testing of these drugs should become a 
routine component of surveillance activities.45
For the first time since the introduction of 
rifampin in the late 1960s, two new drugs for 
the treatment of tuberculosis, bedaquiline and 
delamanid, became available in 2013 and 2014, 
respectively. They have recently been approved 
for the treatment of MDR tuberculosis and are 
already being used in several countries.33 The 
swift establishment of surveillance mechanisms 
to monitor the acquisition of resistance to these 
drugs in patients with MDR tuberculosis and the 
transmission of resistance in the community 
will be of paramount importance to preserve the 
effectiveness of these new agents.
Finally, although challenges exist, future sur-
veys should involve private practitioners, particu-
larly in countries with a large private sector. In 
these settings, drug-resistance surveys in the 
public sector could be complemented by surveys 
in the private sector to determine the magnitude 
of drug resistance as well as the existence and 
direction of any bias introduced by excluding 
private providers from assessments.46 Another 
option is to include private facilities in the survey 
sampling frame and provide incentives for private 
clinics to participate, with the aim of having a 
representative sample.
Conclusions
Data generated at national and global levels have 
allowed the development of an evidence-based 
response to the public health threat posed by 
drug-resistant tuberculosis.47-49 The diagnosis and 
treatment of tuberculosis, including drug-resis-
tant forms, continue to evolve. It is critical that 
methodologic advances be incorporated into the 
approach to ensure that surveillance continues 
to be a key tool to inform policy that is condu-
cive to better control of tuberculosis and drug-
resistant tuberculosis.40
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